Mersana to share interim data of XMT-1536 from ongoing Phase 1 trial
Category: #health  By Pankaj Singh  Date: 2019-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Mersana to share interim data of XMT-1536 from ongoing Phase 1 trial

Clinical-stage biopharmaceutical company Mersana Therapeutics, Inc. has reportedly presented interim efficiency and safety data from its current Phase 1 dose-escalation study evaluating its first-in-class ADC candidate XMT-1536 aimed at NaPi2b, in patients suffering from non-small cell lung (NSCLC) adenocarcinoma, ovarian cancer, and other tumor types. As per trusted sources, the data will be exhibited in a poster session and poster discussion at the 2019 American Society of Clinical Oncology Annual Meeting.

Among the 37 registered patients the tumor types observed include 22 ovarian, primary peritoneal or fallopian tube cancer, eight endometrial, two papillary renal, four NSCLC and one salivary duct cancer. Patients received heavy pre-treatment through a median of 4 prior lines of treatment (range 1-13) for the entire group of patients and a median of 5 lines of pre-treatment for ovarian cancer patients (range 1-11), cited sources close to the development. 

According to sources familiar with the interim results, the most common TRAEs were Grade 1-2 nausea, headache, fatigue and the most frequent Grade-3 TRAE was transient AST elevation. Among patients with tumor types chosen for the strategic expansion phase, specifically NSCLC adenocarcinoma and platinum-resistant ovarian cancer, treated with ≥20 mg/m2 (N=18), 17% showed partial responses and 44% attained stable disease demonstrating a disease control rate of 11/18 (61%), with the treatment period lasting for more than 16 weeks in 9 patients.

Mersana Therapeutics continues to assess patients in the dose escalation period of the clinical trial within the 36 mg/m2 once-every-four-week dose level. On completing the 36 mg/m2 evaluation, the dose that the company expects to go with for the study’s dose expansion phase will be either the 30 mg/m2 dose or the 36 mg/m2 every four weeks dose levels. Moreover, the company is also planning on dosing patients during the dose expansion phase within the third quarter of 2019, reported sources.

Source Credit
http://ir.mersana.com/news-releases/news-release-details/mersana-presents-interim-phase-1-data-xmt-1536-2019-american

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

BioNTech & Genmab initiate trial of DuoBody-PD-L1x4-1BB to treat tumor
BioNTech & Genmab initiate trial of DuoBody-PD-L1x4-1BB to treat tumor
By Pankaj Singh

BioNTech SE, the largest privately held biopharmaceutical company in Europe, recently announced initiation of first-in-human study of DuoBody-PD-L1x4-1BB for the treatment of solid tumors, cite sources. For the record, BioNTech SE is a clinical-stag...

Progenics Pharma initiates clinical trial of 1095 radiotherapy
Progenics Pharma initiates clinical trial of 1095 radiotherapy
By Pankaj Singh

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, has recently announced that its first patient has been dosed for treatment of Metastatic Prostate cancer, in a phase 2 clinical study of 1095 radiotherapy. The clinical study evaluated I-1...

Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG
Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG
By Pankaj Singh

A US-based pharmaceutical company, Aerpio Pharmaceuticals, Inc., recently announced the initiation of Phase 1b clinical trial of AKB-9778 to develop treatment of PAOG (primary open angle glaucoma), report sources. For the record, Aerpio Pharmaceutic...